Post-Marketing surveillance for HPV infection related serious disease in a cohort of Chinese women who received GARDASIL® and GARDASIL®9 (V503-107)

19/11/2026
19/11/2026
EU PAS number:
EUPAS1000001165
Study
Planned
Study type

Study topic

Human medicinal product

Study type

Non-interventional study

Scope of the study

Effectiveness study (incl. comparative)

Data collection methods

Secondary use of data
Non-interventional study

Non-interventional study design

Cohort
Study drug and medical condition

Medicinal product name

Medicinal product name, other

Human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed)
Human papillomavirus 9-valent vaccine (recombinant, adsorbed)

Anatomical Therapeutic Chemical (ATC) code

(J07BM03) papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58)
papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58)
(J07BM01) papillomavirus (human types 6, 11, 16, 18)
papillomavirus (human types 6, 11, 16, 18)

Additional medical condition(s)

Cervical disease
Population studied

Short description of the study population

The study population includes women in Zhejiang Province, China, who received G4 or G9, matched women who did not receive HPV vaccination, and women in the general female population. Vaccinated women are identified from the Zhejiang Province Vaccine Real-World Research Platform (ZVRWP) beginning when G4 and G9 became available in the ZVRWP in 2017 and are followed through approximately 31 December 2026. The general female population includes women with cervical disease diagnosis data available in the ZVRWP.

Age groups

  • Paediatric Population (< 18 years)
    • Children (2 to < 12 years)
    • Adolescents (12 to < 18 years)
  • Adult and elderly population (≥18 years)
    • Adults (18 to < 65 years)
      • Adults (18 to < 46 years)
      • Adults (46 to < 65 years)
    • Elderly (≥ 65 years)
      • Adults (65 to < 75 years)
      • Adults (75 to < 85 years)
      • Adults (85 years and over)
Study design details

Study design

This is an observational cohort study using secondary data from the ZVRWP to conduct post-marketing surveillance of high-grade cervical disease among women who received GARDASIL® or GARDASIL® 9, matched women who did not receive HPV vaccination, and women in the general female population in Zhejiang

Main study objective

The main objective of the study is to monitor the occurrence of high-grade CIN2/3 in women who received G4 or G9 and tested negative for HPV, compared with matched women who did not receive HPV vaccination in Zhejiang Province, China.

Setting

Women in Zhejiang Province, China, included in the ZVRWP, including women vaccinated with G4 or G9 and matched unvaccinated women.

Comparators

Up to 3 unvaccinated women will be matched to each eligible woman in the vaccinated HPV test-negative sub-cohort based on age at enrollment (+/-1 year) and area of residence (urban/rural). The formal comparison of the rates between the vaccinated HPV test-negative sub-cohort and the matched unvaccinated cohort might not be considered meaningful due to the short follow-up period since the introduction of vaccination with G4/G9 and low coverage of cervical screening services in Zhejiang.

Outcomes

The primary outcome is the occurrence of high-grade CIN2/3, AIS, and cervical cancer in women who received G4 or G9 and tested negative for HPV, compared with matched women who did not receive HPV vaccination.

Data analysis plan

Demographics and disease characteristics will be analyzed. For continuous variables, mean, standard deviation (SD), median, interquartile range (IQR), and range will be presented. For categorical variables, the number of patients in each category and percentage will be presented. Rates of high-grade CIN2/3, adenocarcinoma in situ (AIS), and cervical cancer in the cohorts will be estimated with 95% confidence intervals (95% CIs). For the primary and secondary objectives, analyses will be carried out using the available data. A subject with missing data for a given variable will be excluded from the analyses for that variable. No sensitivity analysis will be undertaken.